Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Breast Cancer Tests Adopted by French Hospital Group

NEW YORK (GenomeWeb) – Agendia said today that French hospital group Unicancer has selected its MammaPrint and BluePrint tests for use in a group of 18 comprehensive cancer centers.

The agreement includes centralized testing performed by Agendia in its CLIA-certified, CAP-accredited Amsterdam lab, as well as the provision of next-gen sequencing MammaPrint BluePrint kits, which hospital labs can run in house.

Marjolaine Baldo, Agendia's commercial vice president, EMEA, said in a statement that Unicancer's adoption of its tests is a "significant milestone."

The company promotes MammaPrint and BluePrint as complementary assays, providing both risk and molecular subtyping information. MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.

Agendia received a CE mark for the NGS kit-version of its tests — which uses Agilent Technologies' SureSelect target enrichment system — in March.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.